New approaches to Clostridium difficile colitis therapy
| Autor: | Timothy Leach, Bruce L. Rogers |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Pharmacology
medicine.medical_specialty medicine.drug_class business.industry Antibiotics Disease Ramoplanin Microbiology Clinical trial Food and drug administration Clostridium Difficile Colitis Diarrhea Internal medicine Drug Discovery medicine Molecular Medicine Vancomycin medicine.symptom business medicine.drug |
| Zdroj: | Drug Discovery Today: Therapeutic Strategies. 1:513-517 |
| ISSN: | 1740-6773 |
| DOI: | 10.1016/j.ddstr.2004.11.001 |
| Popis: | Clostrium difficile, a Gram-positive, spore-forming anaerobic bacillus, is one of the most common causes of hospital-acquired diarrhea. The two most important risk factors for C. difficile-associated diarrhea (CDAD) are recent exposure to an antibiotic and exposure to a toxin-producing strain of the organism. Vancomycin is the only agent for the treatment of CDAD that is approved by the Food and Drug Administration (FDA), and there is considerable recent interest in new therapeutic and prophylactic approaches to the disease. Ramoplanin is the most advanced investigational agent still in clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect